Codiak Biosciences Profit Margin

Codiak Biosciences (CDAK) currently reports a profit margin of -87.08% as of September 2022. That compares with -425.26% in the prior-year period — up 79.5% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Codiak Biosciences's profit margin history and peer comparisons.

Codiak Biosciences's profit margin increased from -425.26% to -87.08% — a 79.5% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Codiak Biosciences's profit margin of -87.08% is lower than the Healthcare sector average of 19.13%. That is roughly 555.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Codiak Biosciences's current -87.08% should be judged against Healthcare norms (sector average: 19.13%) and against CDAK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -87.08%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Codiak Biosciences, and consider following CDAK for alerts when major investors trade the stock.